Celltrion’s Omlyclo Gains Rapid Ground in Europe, Expands to 26 Countries
Celltrion’s omalizumab biosimilar Omlyclo is rapidly gaining traction in Europe, with the product now sold in 26 countries across the region. In Spain, Omlyclo’s market share is estimated to have surpassed 90% as of July, while sales in Italy have also exceeded the company’s initial business targets
Celltrion's biosimilar Omlyclo is rapidly expanding its presence in Europe, now sold in 26 countries. Spain has become a dominant market with Omlyclo's market share reaching over 90% in July, while Italy's sales have also surpassed initial targets. The company aims to capitalize on this early success and replicate growth across Europe.
At the 2026 European Respiratory Society Congress in Barcelona, Spain, Celltrion showcased Omlyclo's features and competitive advantages to healthcare professionals. The biosimilar, a version of omalizumab used for chronic spontaneous urticaria and allergic asthma, is available in 75mg, 150mg, and 300mg doses, along with various delivery devices.
Celltrion highlighted the product's storage convenience, stability, latex-free formulation, and ability to ensure a stable supply. They also hosted an "Expert Insights" session featuring a professor of respiratory medicine, discussing clinical benefits, long-term safety, and the potential of biosimilars to improve treatment access and reduce healthcare costs.
Celltrion plans to strengthen its academic, sales, and marketing activities tailored to each European market, while continuing its existing work with tender institutions and expanding its network among hospitals and healthcare professionals involved in prescribing and purchasing decisions.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
